To demonstrate biological relevance and tie our observations with immunocompetent models, we focus on immune mediators of ROS production and use conditional NCF1 knock-in models to show that elevated ROS levels from pharmacological TXNRD1 blockade or from APCs expressing NOX2 are comparable enhancers of B16F10 tumor progression. The gene discussed is TXNRD1; the disease is neoplasm.